当前位置: 首页 >> 检索结果
7349. Trial of Psilocybin versus Escitalopram for Depression.
作者: Robin Carhart-Harris.;Bruna Giribaldi.;Rosalind Watts.;Michelle Baker-Jones.;Ashleigh Murphy-Beiner.;Roberta Murphy.;Jonny Martell.;Allan Blemings.;David Erritzoe.;David J Nutt.
来源: N Engl J Med. 2021年384卷15期1402-1411页
Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking.
7350. Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.
作者: Gregory K Friedman.;James M Johnston.;Asim K Bag.;Joshua D Bernstock.;Rong Li.;Inmaculada Aban.;Kara Kachurak.;Li Nan.;Kyung-Don Kang.;Stacie Totsch.;Charles Schlappi.;Allison M Martin.;Devang Pastakia.;Rene McNall-Knapp.;Sameer Farouk Sait.;Yasmin Khakoo.;Matthias A Karajannis.;Karina Woodling.;Joshua D Palmer.;Diana S Osorio.;Jeffrey Leonard.;Mohamed S Abdelbaki.;Avi Madan-Swain.;T Prescott Atkinson.;Richard J Whitley.;John B Fiveash.;James M Markert.;G Yancey Gillespie.
来源: N Engl J Med. 2021年384卷17期1613-1622页
Outcomes in children and adolescents with recurrent or progressive high-grade glioma are poor, with a historical median overall survival of 5.6 months. Pediatric high-grade gliomas are largely immunologically silent or "cold," with few tumor-infiltrating lymphocytes. Preclinically, pediatric brain tumors are highly sensitive to oncolytic virotherapy with genetically engineered herpes simplex virus type 1 (HSV-1) G207, which lacks genes essential for replication in normal brain tissue.
7351. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.
作者: Andreas Greinacher.;Thomas Thiele.;Theodore E Warkentin.;Karin Weisser.;Paul A Kyrle.;Sabine Eichinger.
来源: N Engl J Med. 2021年384卷22期2092-2101页
Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1 nCov-19, AstraZeneca). More data were needed on the pathogenesis of this unusual clotting disorder.
7352. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.
作者: Nina H Schultz.;Ingvild H Sørvoll.;Annika E Michelsen.;Ludvig A Munthe.;Fridtjof Lund-Johansen.;Maria T Ahlen.;Markus Wiedmann.;Anne-Hege Aamodt.;Thor H Skattør.;Geir E Tjønnfjord.;Pål A Holme.
来源: N Engl J Med. 2021年384卷22期2124-2130页
We report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19). The patients were health care workers who were 32 to 54 years of age. All the patients had high levels of antibodies to platelet factor 4-polyanion complexes; however, they had had no previous exposure to heparin. Because the five cases occurred in a population of more than 130,000 vaccinated persons, we propose that they represent a rare vaccine-related variant of spontaneous heparin-induced thrombocytopenia that we refer to as vaccine-induced immune thrombotic thrombocytopenia.
|